JP2020503280A - ヒドロキシ安息香酸誘導体、その方法および使用 - Google Patents

ヒドロキシ安息香酸誘導体、その方法および使用 Download PDF

Info

Publication number
JP2020503280A
JP2020503280A JP2019530099A JP2019530099A JP2020503280A JP 2020503280 A JP2020503280 A JP 2020503280A JP 2019530099 A JP2019530099 A JP 2019530099A JP 2019530099 A JP2019530099 A JP 2019530099A JP 2020503280 A JP2020503280 A JP 2020503280A
Authority
JP
Japan
Prior art keywords
compound according
mitochondrial
alkyl
aryl
antioxben
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019530099A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020503280A5 (enExample
Inventor
フェルナンダ マルティンス ボルヘス マリア
フェルナンダ マルティンス ボルヘス マリア
ジョルジ グーベア シモエス ダ シルバ オリビエラ パウロ
ジョルジ グーベア シモエス ダ シルバ オリビエラ パウロ
カルロス サントス テイクセラ ホセ
カルロス サントス テイクセラ ホセ
カギデ フェイギン フェルナンド
カギデ フェイギン フェルナンド
カタリーナ ゴメス オリベイラ アナ
カタリーナ ゴメス オリベイラ アナ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Porto
Centro de Neurociencias e Biologia Celular
Original Assignee
University of Porto
Centro de Neurociencias e Biologia Celular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Porto, Centro de Neurociencias e Biologia Celular filed Critical University of Porto
Publication of JP2020503280A publication Critical patent/JP2020503280A/ja
Publication of JP2020503280A5 publication Critical patent/JP2020503280A5/ja
Priority to JP2022200267A priority Critical patent/JP7689690B2/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/54—Quaternary phosphonium compounds
    • C07F9/5442—Aromatic phosphonium compounds (P-C aromatic linkage)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/54—Quaternary phosphonium compounds
    • C07F9/5456—Arylalkanephosphonium compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/55—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/02—Local antiseptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Birds (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2019530099A 2016-12-29 2017-12-29 ヒドロキシ安息香酸誘導体、その方法および使用 Pending JP2020503280A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022200267A JP7689690B2 (ja) 2016-12-29 2022-12-15 ヒドロキシ安息香酸誘導体、その方法および使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PT109818 2016-12-29
PT10981816 2016-12-29
PCT/IB2017/058508 WO2018122789A1 (en) 2016-12-29 2017-12-29 Hydroxybenzoic acid derivatives, methods and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022200267A Division JP7689690B2 (ja) 2016-12-29 2022-12-15 ヒドロキシ安息香酸誘導体、その方法および使用

Publications (2)

Publication Number Publication Date
JP2020503280A true JP2020503280A (ja) 2020-01-30
JP2020503280A5 JP2020503280A5 (enExample) 2021-03-04

Family

ID=61074472

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019530099A Pending JP2020503280A (ja) 2016-12-29 2017-12-29 ヒドロキシ安息香酸誘導体、その方法および使用
JP2022200267A Active JP7689690B2 (ja) 2016-12-29 2022-12-15 ヒドロキシ安息香酸誘導体、その方法および使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022200267A Active JP7689690B2 (ja) 2016-12-29 2022-12-15 ヒドロキシ安息香酸誘導体、その方法および使用

Country Status (8)

Country Link
US (1) US11078222B2 (enExample)
EP (1) EP3562830B1 (enExample)
JP (2) JP2020503280A (enExample)
KR (1) KR102750630B1 (enExample)
CN (1) CN110114365B (enExample)
BR (1) BR112019011303B1 (enExample)
CA (1) CA3048966A1 (enExample)
WO (1) WO2018122789A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3925961A4 (en) * 2019-10-30 2022-05-11 Fusion Biotechnology Co., Ltd. Mitochondria-targeting compound and composition comprising same for treating or preventing aging-related diseases
WO2023053059A1 (en) * 2021-09-30 2023-04-06 Universidade Do Porto Antifouling compound, method and uses thereof
WO2023220365A1 (en) * 2022-05-13 2023-11-16 Virginia Tech Intellectual Properties, Inc. Mitochondrial antioxidant treatment for cask-linked neurodevelopmental disorders
US20260097092A1 (en) * 2022-09-21 2026-04-09 Ulsan National Institute Of Science And Technology Pharmaceutical composition containing mitochondria-targeting compound as active ingredient for treating macular degeneration
KR102894216B1 (ko) * 2022-12-15 2025-12-18 울산과학기술원 Trap-1 억제제
CN116210697B (zh) * 2023-03-02 2024-05-14 西北农林科技大学 反式肉桂酸在提高苹果树腐烂病抗性中的应用
KR20250126454A (ko) * 2024-02-16 2025-08-25 울산과학기술원 암 세포의 티오에스테라제 및 활성산소종에 의해 자가 조립 중합되는 단량체 및 이의 용도

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010126719A1 (en) * 2009-04-27 2010-11-04 Mcw Research Foundation, Inc. Neuroprotective compounds and their use
WO2015075200A1 (en) * 2013-11-22 2015-05-28 Medical Research Council Mitochondria-targeted dicarbonyl sequestering compounds
JP2019537623A (ja) * 2016-10-14 2019-12-26 ウニヴェルシダージ ド ポルトＵｎｉｖｅｒｓｉｄａｄｅ Ｄｏ Ｐｏｒｔｏ ヒドロキシケイ皮酸誘導体、その方法および使用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018010829A (es) * 2016-03-08 2019-02-07 Univ Michigan Regents Inductores de molécula pequeña de especies de oxígeno reactivo e inhibidores de la actividad mitocondrial.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010126719A1 (en) * 2009-04-27 2010-11-04 Mcw Research Foundation, Inc. Neuroprotective compounds and their use
WO2015075200A1 (en) * 2013-11-22 2015-05-28 Medical Research Council Mitochondria-targeted dicarbonyl sequestering compounds
JP2019537623A (ja) * 2016-10-14 2019-12-26 ウニヴェルシダージ ド ポルトＵｎｉｖｅｒｓｉｄａｄｅ Ｄｏ Ｐｏｒｔｏ ヒドロキシケイ皮酸誘導体、その方法および使用
JP7111730B2 (ja) * 2016-10-14 2022-08-02 ウニヴェルシダージ ド ポルト ヒドロキシケイ皮酸誘導体、その方法および使用

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
ASIN-CAYUELA, J. ET AL.: "Fine-tuning the hydrophobicity of amitochondria-targeted antioxidant", FEBS LETTERS, vol. 571, JPN6021030669, 2004, pages 9 - 16, ISSN: 0004613325 *
CORTES, LEONEL A. ET AL.: "Novel Gallate Triphenylphosphonium Derivatives with Potent Antichagasic Activity", PLOS ONE, vol. 10(8), JPN7021004174, 2015, pages 0136852 - 1, ISSN: 0004849473 *
HUANG, S. ET AL.: "New photostable naphthalimide-based fluorescent probe for mitochondrial imaging and tracking", BIOSENSORS & BIOELECTRONICS, vol. 71, JPN7021004173, 2015, pages 313 - 321, ISSN: 0004613322 *
MOSSALAM, M. ET AL.: "Solid Phase Synthesis of Mitochondrial Triphenylphosphonium-Vitamin E Metabolite Using a Lysine Link", PLOS ONE, vol. 8(1), JPN7021004175, 2013, pages 53272, ISSN: 0004613323 *
SANDOVAL-ACUNA, C. ET AL.: "Destabilization of mitochondrial functions as a target against breast cancer progression: Role of TP", TOXICOLOGY AND APPLIED PHARMACOLOGY, vol. 309, JPN6021039306, 2016, pages 2 - 14, ISSN: 0004849474 *
TEIXEIRA, J. ET AL.: "Rational discovery and development of a mitochondria-targeted antioxidant based on cinnamic acid sca", FREE RADICAL RESEARCH, vol. 46, no. 5, JPN6021030665, 2012, pages 600 - 611, ISSN: 0004613324 *

Also Published As

Publication number Publication date
US11078222B2 (en) 2021-08-03
KR20190132622A (ko) 2019-11-28
BR112019011303B1 (pt) 2023-03-14
EP3562830A1 (en) 2019-11-06
WO2018122789A1 (en) 2018-07-05
JP2023051961A (ja) 2023-04-11
JP7689690B2 (ja) 2025-06-09
CN110114365B (zh) 2022-12-13
KR102750630B1 (ko) 2025-01-06
CA3048966A1 (en) 2018-07-05
BR112019011303A2 (pt) 2019-10-08
EP3562830B1 (en) 2023-06-07
US20190330249A1 (en) 2019-10-31
EP3562830C0 (en) 2023-06-07
CN110114365A (zh) 2019-08-09

Similar Documents

Publication Publication Date Title
JP7689690B2 (ja) ヒドロキシ安息香酸誘導体、その方法および使用
JP7111730B2 (ja) ヒドロキシケイ皮酸誘導体、その方法および使用
Estrada et al. New cinnamic–N-benzylpiperidine and cinnamic–N, N-dibenzyl (N-methyl) amine hybrids as Alzheimer-directed multitarget drugs with antioxidant, cholinergic, neuroprotective and neurogenic properties
Teixeira et al. Development of hydroxybenzoic-based platforms as a solution to deliver dietary antioxidants to mitochondria
Spoerlein-Guettler et al. Ferrocene and (arene) ruthenium (II) complexes of the natural anticancer naphthoquinone plumbagin with enhanced efficacy against resistant cancer cells and a genuine mode of action
Silvia et al. Novel molecular combination deriving from natural aminoacids and polyphenols: Design, synthesis and free-radical scavenging activities
Bai et al. Targeting (cellular) lysosomal acid ceramidase by B13: Design, synthesis and evaluation of novel DMG-B13 ester prodrugs
Chavarria et al. Exploring cinnamic acid scaffold: development of promising neuroprotective lipophilic antioxidants
Cabrera et al. In vivo phase II-enzymes inducers, as potential chemopreventive agents, based on the chalcone and furoxan skeletons
Basilico et al. Modified quaternary ammonium salts as potential antimalarial agents
EP3129014B1 (fr) Nouveaux composes organo-selenies, procédé de fabrication et applications en pharmacie comme agents anti-tumoraux
Bai et al. Synthesis and bioevaluation of ω-N-amino analogs of B13
Šimunović et al. Urea and carbamate derivatives of primaquine: Synthesis, cytostatic and antioxidant activities
Koufaki et al. Synthesis of tropolone derivatives and evaluation of their in vitro neuroprotective activity
Bao et al. Novel anticancer hybrids from diazen-1-ium-1, 2-diolate nitric oxide donor and ROS inducer plumbagin: Design, synthesis and biological evaluations
Rajić et al. Primaquine-NSAID twin drugs: Synthesis, radical scavenging, antioxidant and Fe2+ chelating activity
Fu et al. Identification of nitric oxide-releasing derivatives of oleanolic acid as potential anti-colon cancer agents
Wang et al. Efficient synthesis and antioxidant activities of N-heterocyclyl substituted Coenzyme Q analogues
JP6879993B2 (ja) カルボニルストレス及び酸化ストレスに対して活性な、金属及び／又はフリーラジカルキレート化モチーフと会合する近接第１級ジアミン、並びにその使用
EP2909171B1 (fr) Composés 3,4-bis(catéchol)pyrrole n-substitués, leur préparation et utilisation dans le traitement du cancer
Odens et al. Inhibition of the thioesterase activity of human fatty acid synthase by 1, 4-and 9, 10-diones
EP3353186B1 (en) Highly efficient nrf2 activators-co-releasing molecule hybrids, their use in the treatment of inflammatory or cardiovascular diseases and their process of preparation
BR112019007565B1 (pt) Derivados hidroxicinâmicos, métodos e usos dos mesmos
WO2014174583A1 (ja) 新規美白剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201224

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210107

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210120

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210916

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211012

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220111

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220314

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220408

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220816